Medicine Overview of Velvin Injection 10mg/vial Injection
Velvin Injection is an anti-cancer medication used in the treatment of breast cancer, kidney cancer, Hodgkin’s disease, and Non-Hodgkin’s lymphoma.
Velvin Injection is given as an injection into the vein under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
The most common side effects of this medicine include nausea, vomiting, diarrhea, and decreased appetite. This medicine may reduce the number of blood cells (white blood cells) in your blood, thereby, increasing the susceptibility to infections and fever. In some cases, it may also cause kidney disease related to uric acid level. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.
Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy. You should take precautions while taking this medication as it may cause inflammation of mouth and lips and neurological toxicity.
- Breast cancer
- Kidney cancer
- Hodgkin’s disease
- Non-Hodgkin's lymphoma
- Nausea
- Vomiting
- Decreased appetite
- Decreased white blood cell count
- Diarrhea
-
In males vinblastine may cause aspermia (lack of semen causing infertility); in females vinblastine may cause amenorrhea (absence of menstruation), which may recover after some duration.
-
Take precautions while taking vinblastine as it may cause inflammation of mouth and lips (stomatitis) and neurological toxicity.
-
Avoid even accidental contamination of eyes with vinblastine, as it may cause severe irritation.
-
Vinblastine may cause acute kidney disease (nephropathy) related to uric acid level.
-
Tell your doctor if you are or planning to become pregnant or are breastfeeding.
IV Preparation
IV push
1 mg/mL (dose/syringe); max syringe size for IVP is a 30 mL syringe & syringe should be <75% full
Powder: reconstitute w/ 10 mL NS or bacteriostatic NS to obtain 1 mg/mL soln
Continuous infusion: 250-1000 mL D5W or NS (dose)
Intravenous
Cancers
Testicular CA, Squamous cell CA of head & neck, Hodgkin’s Dz, Kaposi’s sarcoma; histiocytic lymphoma, mycosis fungoides, & Letterer-Siwe disease (histiocytosis X)
General Dosing Ranges
3.7-18 mg/sq.meter/day IV q7-10d
1st dose 3.7 mg/sq.meter/day IV
Incr by 1.85 mg/sq.meter qweek until WBC equal 3000/cu.mm
NMT 18.5 mg/sq.meter
Hepatic impairment
Decrease dose by half if bilirubin >3 mg/dL [>51 umol/L]
Intravenous
Cancers
Testicular CA, Squamous cell carcinoma CA of head & neck, Hodgkin’s Dz, Kaposi’s sarcoma; histiocytic lymphoma, mycosis fungoides, & Letterer-Siwe disease (histiocytosis X)
General dosing ranges
2.5- 12.5 mg/sq meter IV q7-10d
1st dose 2.5 mg/sq.meter IV
Incr by 1.25 mg/sq.meter qWeek until WBC = 3000/cu.mm
No more than 12.5 mg/sq.meter
Hepatic impairment; neurotoxicity; ischemic heart disease; preexisting pulmonary dysfunction; extravasation may cause tissue damage and pain. Discontinue immediately if extravasation occurs, with local Inj of hyaluronidase and local heat application to decrease discomfort and risk of cellulitis; remaining Inj to be injected into another vein. Routine prophylaxis against constipation recommended especially in high doses. Nadir in leukocyte count occur 4-10 days after vinblastine admin; recovery observed 7-14 days after treatment.
Lactation: not known if excreted in breast milk, do not nurse
1-10%
Anemia,Leukopenia,Myelosuppression,Alopecia
Frequency Not Defined
Peripheral neuropathy,Hypertension,Bronchospasm,Nausea,Vomiting,Anorexia,Diarrhea,Constipation,Paralytic ileus,Jaw pain,Aspermia,Amenorrhea
Possible increase in vinblastine levels with aprepitant. Reduced vinblastine metabolism with miconazole. Variable interactions with phenytoin, monitor serum phenytoin levels. Reduced immune response with vaccines. Additive myelotoxicity with zidovudine. Concurrent admin of vinblastine with CYP3A inhibitors may cause an earlier onset and/or an increased severity of side effects.
Potentially Fatal: Increased toxicity of vinblastine with erythromycin. Increased neurotoxicity and myelotoxicity with azole antifungals e.g. itraconazole and posaconazole. Increased risk of severe neutropenia with ritonavir. Increased risk of acute pulmonary toxicity with mitomycin. Increased toxicity when ganciclovir is given with, immediately before or after vinblastine.
Reviews
Clear filtersThere are no reviews yet.